Research Methods Poster Session 2023
 

Files

Download

Download Poster (714 KB)

Description

Triple-negative breast cancer (TNBC) is an aggressive form of subtype breast cancer and there are currently new treatments being discovered such as the combination of immunotherapy and chemotherapy. In immunotherapy against triple-negative breast cancer, checkpoint inhibitors like PD-1/PD-L1 treat TNBC by blocking the “off” signal that prevents T-cells from killing cancer cells. As a group, we conducted a meta-narrative review collecting results from primary sources such as clinical trials and human experimental studies to support our research question on how PD-L1 inhibitor treatments compare to other treatments in patients with TNBC. The review included articles searched from Embase, Pubmed, EMBASE, and Cochrane Library for randomized controlled trials, clinical trials, and case studies published within 5 years. The articles relate to PD-1/PD-L1 inhibitors combined with chemotherapy or PD-L1 immunotherapy for triple-negative breast cancer. The results found that PD-L1 immunotherapy treatment in combination with other forms of traditional cancer therapy, such as radiation and chemotherapy, had a slightly significant positive response. However, the treatment was overwhelmingly successful in patients who exhibited PD-L1 positive TNBC compared to patients who were PD-L1 negative. Secondly, and a major concern for immunotherapy treatment is the adverse events, potentially developing autoimmune diseases. From the articles pulled, there seemed to be no new adverse events that developed for patients outside the standard toxic effects found from radiation and chemotherapy treatment.

DOI

https://doi.org/10.52519/00112

Program

Histotechnology

Publication Date

2023

City

Houston

Keywords

Triple-negative breast cancer, PD-1/PD-L1, Immunotherapy, Meta-Narrative review

Disciplines

Biology | Immunology and Infectious Disease | Immunotherapy | Life Sciences | Other Immunology and Infectious Disease

Meta-Narrative Review of PD-L1 by immunotherapy on Triple-Negative Breast Cancer

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.